March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Silence Therapeutics
(NASDAQ:SLN)
Intraday
$21.60
-0.22
[-1.01%]
After-Hours
$21.60
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$21.60
-0.22
[-1.01%]
At close: Mar 28
$21.60
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Silence Therapeutics Stock (NASDAQ:SLN)
Silence Therapeutics Stock (NASDAQ: SLN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 15, 2024
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga Newsdesk
-
Mar 15, 2024, 12:57PM
Thursday, March 14, 2024
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Avi Kapoor
-
Mar 14, 2024, 2:01PM
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $45
Benzinga Newsdesk
-
Mar 14, 2024, 12:33PM
Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42
Benzinga Newsdesk
-
Mar 14, 2024, 7:54AM
Wednesday, March 13, 2024
What 4 Analyst Ratings Have To Say About Silence Therapeutics
Benzinga Insights
-
Mar 13, 2024, 4:01PM
HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga Newsdesk
-
Mar 13, 2024, 11:34AM
What's Going On With Silence Therapeutics Stock Today?
Nabaparna Bhattacharya
-
Mar 13, 2024, 10:16AM
Silence Therapeutics Reported 2023 Revenue of £25.4M, EPS Loss of £(38.9), Cash Balance of £54.0M
Benzinga Newsdesk
-
Mar 13, 2024, 7:09AM
Silence Therapeutics Announces Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Benzinga Newsdesk
-
Mar 13, 2024, 7:01AM
Earnings Scheduled For March 13, 2024
Benzinga Insights
-
Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Earnings Scheduled For March 12, 2024
Benzinga Insights
-
Mar 12, 2024, 5:35AM
Friday, February 23, 2024
Silence Therapeutics Achieves $10M Milestone Payment From AstraZeneca Collaboration Following The Initiation Of Phase 1 Trial
Benzinga Newsdesk
-
Feb 23, 2024, 8:05AM
Thursday, February 22, 2024
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga Newsdesk
-
Feb 22, 2024, 9:04AM
Monday, February 05, 2024
Silence Therapeutics Announces Oversubscribed $120M Private Placement Of 5,714,286 ADS At $21.00/ADS
Benzinga Newsdesk
-
Feb 5, 2024, 8:18AM
Wednesday, January 31, 2024
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Jan 31, 2024, 11:02AM
Silence Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and $67 price target.
Benzinga Newsdesk
-
Jan 31, 2024, 10:27AM
BMO Capital Initiates Coverage On Silence Therapeutics with Outperform Rating, Announces Price Target of $67
Benzinga Newsdesk
-
Jan 31, 2024, 6:00AM
Thursday, January 18, 2024
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Benzinga Newsdesk
-
Jan 18, 2024, 6:08AM
Wednesday, December 13, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Dec 13, 2023, 12:31PM
Friday, November 17, 2023
HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Lowers Price Target to $75
Benzinga Newsdesk
-
Nov 17, 2023, 6:20AM
Wednesday, November 01, 2023
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
Vandana Singh
-
Nov 1, 2023, 4:09PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Nov 1, 2023, 1:31PM
Silence Therapeutics Reports Topline Results From Phase 1 Multiple Dose Study Of Zerlasiran; Lp(a) Levels Remained Around 90% Lower Than Baseline At Study Endpoint
Benzinga Newsdesk
-
Nov 1, 2023, 7:12AM
Thursday, August 17, 2023
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price Target
Benzinga Newsdesk
-
Aug 17, 2023, 12:42PM
Where Silence Therapeutics Stands With Analysts
Benzinga Insights
-
Aug 17, 2023, 12:00PM
Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target
Benzinga Newsdesk
-
Aug 17, 2023, 7:47AM
Thursday, August 10, 2023
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Monday, July 24, 2023
Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Jul 24, 2023, 9:40AM
Monday, July 17, 2023
Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Jul 17, 2023, 10:40AM
Monday, June 26, 2023
What 6 Analyst Ratings Have To Say About Silence Therapeutics
Benzinga Insights
-
Jun 26, 2023, 2:01PM
Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Jun 26, 2023, 9:39AM
Tuesday, June 20, 2023
Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Jun 20, 2023, 9:21AM
Monday, June 12, 2023
Morgan Stanley Reiterates Overweight on Silence Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk
-
Jun 12, 2023, 10:09AM
Thursday, May 18, 2023
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price Target
Benzinga Newsdesk
-
May 18, 2023, 6:08AM
Tuesday, May 16, 2023
Silence Therapeutics Reports Q1 2023 Results; Revenue Recognized For The Quarter Ending March 31, 2023 Was £11.4M Vs £5.7M YoY
Happy Mohamed
-
May 16, 2023, 4:02PM
Thursday, May 11, 2023
The Latest Analyst Ratings for Silence Therapeutics
Benzinga Insights
-
May 11, 2023, 2:00PM
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price Target
Benzinga Newsdesk
-
May 11, 2023, 6:25AM
Monday, May 08, 2023
Silence Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $20 price target.
Benzinga Newsdesk
-
May 8, 2023, 11:51AM
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Benzinga Insights
-
May 8, 2023, 11:00AM
Morgan Stanley Initiates Coverage On Silence Therapeutics with Overweight Rating, Announces Price Target of $20
Benzinga Newsdesk
-
May 8, 2023, 5:02AM
Thursday, May 04, 2023
Silence Therapeutics Achieves $10M Milestone Payment From AstraZeneca Collaboration
Benzinga Newsdesk
-
May 4, 2023, 7:20AM
Monday, May 01, 2023
Silence Therapeutics Has Completed Enrollment In The ALPACAR-360 Phase 2 Study Of Zerlasiran (SLN360) In Subjects With Elevated Lipoprotein At High Risk Of Atherosclerotic Cardiovascular Disease Events
Benzinga Newsdesk
-
May 1, 2023, 7:24AM
Tuesday, April 25, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Apr 25, 2023, 1:33PM
Monday, April 24, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Apr 24, 2023, 2:12PM
Friday, April 21, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Apr 21, 2023, 1:11PM
Monday, April 17, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Apr 17, 2023, 9:06AM
Wednesday, March 29, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Mar 29, 2023, 2:46PM
Tuesday, March 28, 2023
Silence Therapeutics Will Be Acquiring Back Exclusive Worldwide Rights To Two siRNA Drug Targets Under The Collaboration Agreement With Mallinckrodt Pharmaceuticals For Complement-mediated Diseases
Benzinga Newsdesk
-
Mar 28, 2023, 7:09AM
Friday, March 17, 2023
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price Target
Benzinga Newsdesk
-
Mar 17, 2023, 11:30AM
Thursday, March 16, 2023
Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $26
Benzinga Newsdesk
-
Mar 16, 2023, 7:39AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch